ArcticZymes granted patent protection on its heat-labile Salt Active Nuclease in the USA
ArcticZymes AS has received a Notice of Allowance for the United States Patent Application No. US9422595 covering patentable subject matter of its heat-labile Salt Active Nuclease (HL-SAN) product.
With the approval of the new patent in the USA, ArcticZymes strengthens its rapidly growing intellectual property portfolio. The patent extends protection in the USA to the nucleic acid sequence of its HL-SAN product. The enzyme is an endonuclease capable of operating at high salt concentrations. This opens up a wider utility for use of such enzymes.
“The HL-SAN portfolio has typically been utilized by our customers in the preparation of nucleic acid-free products such as recombinant proteins and reagents. More recently, it has attracted growing interest from manufacturers of adeno-associated virus (AAV) for utility in gene therapy. The new patent greatly strengthens our commercial efforts.” says Managing Director, Jethro Holter at ArcticZymes AS.